Skip to Content
Merck

616431

Sigma-Aldrich

Tranylcypromine, HCl

≥97% (HPLC), monoamine oxidase and histone demethylase inhibitor, solid

Synonym(s):

Tranylcypromine, HCl, Histone Lysine Demethylase Inhibitor I, LSD Inhibitor V, Monoamine Oxidase Inhibitor I, Parnate, 2-PCPA, TCP, (1R)-2-Phenylcyclopropan-1-amine, HCl, trans-2-Phenylcyclopropylamine, HCl, BHC110 Inhibitor V, KDM1 Inhibitor V, LSD1 Inhibitor V, LSD2 Inhibitor I, MOA Inhibitor I, Histone Lysine Demethylase Inhibitor I, LSD Inhibitor V, Monoamine Oxidase Inhibitor I, Parnate, 2-PCPA, TCP, (1R)-2-Phenylcyclopropan-1-amine, HCl, trans-2-Phenylcyclopropylamine, HCl, BHC110 Inhibitor V, LSD2 Inhibitor I, MOA Inhibitor I,

Sign Into View Organizational & Contract Pricing

Select a Size



About This Item

Empirical Formula (Hill Notation):
C9H11N · xHCl
CAS Number:
Molecular Weight:
133.19 (free base basis)
MDL number:
UNSPSC Code:
51111800
NACRES:
NA.77

Product Name

Tranylcypromine, HCl, A cell-permeable phenylcyclopropylamine that inhibits the monoamine oxidase and histone demethylase activities.

Quality Level

Assay

≥97% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
desiccated (hygroscopic)
protect from light

color

white to yellow

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

Cl.N[C@@H]1[C@H](C1)c2ccccc2

InChI

1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m1./s1

InChI key

ZPEFMSTTZXJOTM-RJUBDTSPSA-N

General description

A cell-permeable phenylcyclopropylamine that inhibits the monoamine oxidase and histone demethylase activities, respectively, of MAO A/B (Ki = 101.9 and 16.0 M, respectively) and LSD1/2 (Ki = 242.7 and 180.0 M, respectively), four members of a flavin-dependent amine oxidase family enzymes, by a covalent adduct formation with the enzyme-bound FAD. In addition to preventing LSD1-CoREST (Corepressor of RE1-Silencing Transcription factor) complex-mediated H3K4 demethylation (IC50<2 M), TCP also inhibits LSD1-HCF-1 (Host Cell Factor-1) complex-mediated H3K9 demethylase activity, which is demonstrated to be an essential mechanism for the replication and latent infection of the α-herpesviruses HSV and VZV. The combined treatment of 2 M TCP and 10 M CHIR99061 is reported to enable the reprogramming of Oct4/Klf4-transduced primary HNEKs (Human Neonatal Epidermal Keratinocytes) into iPS (induced Pluripotent Stem) cells, albeit at a 100-time lower efficiency as seen in cultures transduced with 4-TFs (Oct44, Klf4, Sox2, and c-Myc).

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Liang, Y., et al. 2009. Nat. Med.15, 1312.
Li, W., et al. 2009. Stem Cells27, 2992.
Karytinos, A., et al. 2009. J. Biol. Chem.284, 17775.
Hruschka, S., et al. 2008. Bioorg. Med. Chem.16, 7148.
Schmidt, D.M., and McCafferty, D.G. 2007. Biochemistry46, 4408.
Lee, M.G., et al. 2006. Chem. Biol.13, 563.
Yoshida, S., et al. 2004. Bioorg. Med. Chem.12, 2645.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Pictograms

Skull and crossbones

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 3 Oral

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service